Skip to main content

Simponi Aria FDA Approval History

Last updated by Judith Stewart, BPharm on Oct 5, 2020.

FDA Approved: Yes (First approved July 18, 2013)
Brand name: Simponi Aria
Generic name: golimumab
Dosage form: Injection
Company: Janssen Biotech, Inc.

Simponi Aria (golimumab) is a tumor necrosis factor (TNF) blocker indicated for the treatment of:

Development timeline for Simponi Aria

Sep 30, 2020Approval Simponi Aria (golimumab) Approved by the FDA for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
Oct 20, 2017Approval FDA Approves Simponi Aria (golimumab) for the Treatment of Adults With Active Psoriatic Arthritis or Active Ankylosing Spondylitis
Jul 19, 2013Approval Simponi Aria (golimumab) for Infusion Receives FDA Approval for Treatment of Moderately to Severely Active Rheumatoid Arthritis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.